Niewydolność serca indukowana trastuzumabem – czy zawsze udaje się skutecznie leczyć? Case report
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2014
Słowa kluczowe:
trastuzamab, kardiotoksyczność typu II, rak piersi
##plugins.themes.bootstrap3.article.main##
Abstrakt
Dysfunkcja skurczowa lewej komory serca pojawiająca się podczas terapii trastuzumabem określana jest mianem kardiotoksyczności typu II. Jako główną jej cechę wskazuje się całkowitą odwracalność po odstawieniu trastuzumabu i ewentualnym zastosowaniu leków kardiologicznych. Pewien odsetek chorych nie doświadcza jednak pełnej normalizacji funkcji skurczowej serca. Przyczyny tego niekorzystnego rokowania są przedmiotem licznych dyskusji.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Szmit S, Kownacki Łukasz, Torbicki A. Niewydolność serca indukowana trastuzumabem – czy zawsze udaje się skutecznie leczyć?. OncoReview [Internet]. 30 czerwiec 2014 [cytowane 23 listopad 2024];4(2(14):62-8. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/361
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Ewer MS, Lippman SM. Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity. J Clin Oncol 2005; 23: 2900-2902.
2. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23(31): 7820-6.
3. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221.
4. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23(31): 7820-6.
5. Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26(8): 1231-8.
6. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005; 23(31): 7811-9.
7. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25(25): 3859-65.
8. Procter M, Suter TM, de Azambuja E et al. Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. J Clin Oncol 2010; 28: 3422-3428.
9. Russell SD, Blackwell KL, Lawrence J et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamidefollowed by trastuzumab adjuvant therapy:a combined review of cardiac data from the National Surgical Adjuvantbreast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010; 28(21): 3416-21.
10. Szmit S, Kurzyna M, Glówczynska R et al. Manageability of acute severe heart failure complicated with left ventricular thrombosis during therapy for breast cancer. Int Heart J 2010; 51(2): 141-5.
11. Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin i evaluation. J Clin Oncol 2010; 28: 3910-3916.
12. Curigliano G, Cardinale D, Suter T et al. on behalf of the ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines Annals of Oncology 23 (Supplement 7): vii155–vii166, 2012.
13. Steingart RM, Yadav N, Manrique C et al. Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. Semin Oncol. 2013; 40(6): 690-708.
14. Druck MN, Gulenchyn KY, Evans WK et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer 1984; 53(8): 1667-74.
15. Tarantini L, Cioffi G, Gori S, et al; Italian Cardio-Oncologic Network. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 2012; 18(2): 113-9.
16. Fallah-Rad N, Walker JR, Wassef A et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011; 57(22): 2263-70.
17. Negishi K, Negishi T, Haluska BA et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 2014; 15(3): 324-31.
2. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23(31): 7820-6.
3. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221.
4. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23(31): 7820-6.
5. Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26(8): 1231-8.
6. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005; 23(31): 7811-9.
7. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25(25): 3859-65.
8. Procter M, Suter TM, de Azambuja E et al. Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. J Clin Oncol 2010; 28: 3422-3428.
9. Russell SD, Blackwell KL, Lawrence J et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamidefollowed by trastuzumab adjuvant therapy:a combined review of cardiac data from the National Surgical Adjuvantbreast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010; 28(21): 3416-21.
10. Szmit S, Kurzyna M, Glówczynska R et al. Manageability of acute severe heart failure complicated with left ventricular thrombosis during therapy for breast cancer. Int Heart J 2010; 51(2): 141-5.
11. Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin i evaluation. J Clin Oncol 2010; 28: 3910-3916.
12. Curigliano G, Cardinale D, Suter T et al. on behalf of the ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines Annals of Oncology 23 (Supplement 7): vii155–vii166, 2012.
13. Steingart RM, Yadav N, Manrique C et al. Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. Semin Oncol. 2013; 40(6): 690-708.
14. Druck MN, Gulenchyn KY, Evans WK et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer 1984; 53(8): 1667-74.
15. Tarantini L, Cioffi G, Gori S, et al; Italian Cardio-Oncologic Network. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 2012; 18(2): 113-9.
16. Fallah-Rad N, Walker JR, Wassef A et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011; 57(22): 2263-70.
17. Negishi K, Negishi T, Haluska BA et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 2014; 15(3): 324-31.